Kidney Cancer

Various immunotherapy/TKI regimens were observed to determine the impact on survival in patients with metastatic renal cell carcinoma.

Collecting and analyzing patient data through an AI tool may help with more accurately predicting outcomes and personalizing treatment.

Data from CheckMate 214 show a steady improvement in overall survival with nivolumab/ipilimumab in patients with favorable-risk disease.

Developers designed ADI-270 to potentially improve clinical responses in patients with renal cell carcinoma and other CD70-positive tumors.

A minimally invasive cryoablation technology system designed to treat patients with kidney tumors and elicit an 89.65% recurrence-free rate.

“Our analysis showed that the time to progression was later with the use of lenvatinib and pembrolizumab compared with sunitinib,” said Viktor Grünwald, MD, PhD.

Using the TILs CD8-positive, PD-1-positive, TIM3-negative, and LAG3-negative as predictive biomarkers did not impact outcomes in metastatic clear cell renal cell carcinoma.

Treatment with DFF332 appears to be safe and tolerable across all dose levels, according to Sumanta Kumar Pal, MD.

Hans Hammers, MD, and his team discuss the most pertinent treatment options for patients with renal cell carcinoma.

Matthew T. Campbell, MD, MS, discusses CAR T-cell therapy and immunotherapy advances in renal cell carcinoma.

Moshe Ornstein, MD, highlights recent treatment updates for renal cell carcinoma.

Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.

Molecular profiling is a tool that can best determine first-line therapy options for patients with advanced RCC.

Clinicians are learning how to identify adverse effects relating to either immunotherapy or tyrosine kinase inhibitors for patients with advanced renal cell carcinoma.

Moshe Ornstein, MD, discusses the heterogeneous population that comprise patients with advanced renal cell carcinoma.

Toripalimab plus axitinib is now an approved regimen in China for patients with medium- to high-risk unresectable or metastatic renal cell carcinoma.

Findings from a phase 2 trial highlight an acceptable adverse effect profile and renal function with stereotactic ablative body radiotherapy in primary renal cell cancer.

Sumanta Kumar Pal, MD, FASCO, provides advice for community oncologists, and the Oncology Brothers review key points from the discussion.

Focusing on advanced kidney cancer, medical oncologists offer clinical perspectives on treatment in the second line and beyond.

The Oncology Brothers and Sumanta Kumar Pal, MD, FASCO, offer comprehensive insights on the treatment of patients with metastatic kidney cancer.

Sumanta Kumar Pal, MD, FASCO, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss risk stratification and treatment practices for patients with localized kidney cancer following surgery.

Practices should not differentiate treatment options based on race for patients with metastatic renal cell carcinoma, according to Jasmeet Kaur, MD.

Treatment with belzutifan increased the time to disease progression, according to findings from the LITESPARK-005 trial.

Findings from the phase 3 CheckMate 67T trial showed noninferiority of subcutaneous nivolumab when compared with intravenous nivolumab.

Adjuvant pembrolizumab resulted in a reduction in the risk of death in patients with ccRCC.